This finding is consistent with earlier studies from CPS-II where longer T2DM duration and insulin use were associated with invasive, and not with noninvasive, bladder cancer incidence (34) and self-reported T2DM was associated with increased bladder cancer mortality (29). The gene discussed is INS; the disease is urinary bladder carcinoma.